Since systemic MCL-1 inhibition with currently available inhibitors leads to normal tissue toxicity and lethality when combined with a BCL-XL inhibitor/PROTAC, we sought to identify a strategy to selectively suppress MCL-1 expression in SCLC cells. Here, BCL2L1 is linked to small cell lung carcinoma.